B7.2-AML vaccine

B7.2-AML vaccine is an experimental cellular immunotherapy designed for the treatment of acute myeloid leukemia (AML). It consists of AML cells that have been genetically modified, typically via retroviral transduction, to express the B7.2 (CD86) costimulatory molecule on their surface. B7.2 is a critical ligand that binds to CD28 on T cells, providing the necessary "second signal" for full T-cell activation and proliferation. By expressing this molecule directly on the surface of leukemic cells, the vaccine aims to bypass the requirement for professional antigen-presenting cells and directly activate CD8+ cytotoxic T lymphocytes to recognize and attack the tumor. Preclinical research conducted at the Dana-Farber Cancer Institute demonstrated that while B7.2-AML cells could be rejected by the immune system in murine models, the vaccine was less potent than GM-CSF-secreting AML vaccines in establishing long-term systemic immunity and did not progress to clinical development as a standalone agent.

Other names

CD86-AML vaccineCD-86-AML vaccineCD 86-AML vaccineB7.2-transfected AML cellsB-7.2-transfected AML cellsB 7.2-transfected AML cellsCD86-expressing AML cell vaccineCD-86-expressing AML cell vaccineCD 86-expressing AML cell vaccine